@article{7977d286641040888450eb09987345da,
title = "Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement",
author = "Shweta Deshpande and Gertz, {Morie A.} and Angela Dispenzieri and Kumar, {Shaji S.} and Parikh, {Sameer A.} and Eli Muchtar",
note = "Funding Information: Shweta Deshpande: None; Morie A. Gertz: Consultancy (Millenium) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis). Angela Dispenzieri: Research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). Shaji Kumar: Consultancy (Celgene, Millennium, Onyx, Janssen, and BMS); and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). Sameer A. Parikh: Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, and Ascentage Pharma for clinical studies in which Sameer A.Parikh is a principal investigator. Sameer A.Parikh has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, and AbbVie (he was not personally compensated for his participation). Eli Muchtar: None.",
year = "2020",
month = jun,
day = "6",
doi = "10.1080/10428194.2020.1737688",
language = "English (US)",
volume = "61",
pages = "1752--1755",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",
}